Neuronetics — Third Quarter 2026 Earnings Summary

Neuronetics reported third-quarter 2026 total revenue of $42.0 million, representing a 12.5% increase year-over-year driven by a 20.1% rise in Greenbrook revenue to $26.2 million. The company achieved an adjusted EBITDA of $1.9 million and a net loss of $1.6 million, marking significant improvements from the corresponding period in 2025. Operational milestones included the submission of a 510(k) application for accelerated TMS, a new distribution agreement with Wave Neuro for PTSD treatment, and the launch of an integration between NeuroStar's TrakStar platform and AdvancedMD's EHR system. For the full year 2026, Neuronetics maintains its revenue guidance between $160 million and $164 million while narrowing its projected operating expense range.